医学
糖尿病
2型糖尿病
重症监护医学
2型糖尿病
肥胖
临床试验
疾病
赛马鲁肽
生物信息学
内科学
利拉鲁肽
内分泌学
生物
作者
Rami A. Al‐Horani,Kholoud F. Aliter,Hashem Aliter
出处
期刊:Current Diabetes Reviews
[Bentham Science]
日期:2024-01-23
卷期号:20
标识
DOI:10.2174/0115733998276832231124170324
摘要
Abstract: Diabetes is a chronic illness that can become debilitating owing to its microvascular and macrovascular complications. Its prevalence is increasing and so is its cost. Diabetes, particularly type 2, appears to have a very close relationship with obesity. While lifestyle modifications, exercises, and current therapeutics have substantially improved clinical outcomes, the need for new therapeutics and regimens continue to exist. Several new medications and regimens for diabetes, obesity, and diabesity are showing promising results in advanced clinical trials. For type 1 diabetes mellitus (T1DM), they include teplizumab, ustekinumab, jakinibs, and cell therapies, whereas for type 2 diabetes mellitus (T2DM), they include once-weakly insulin, tirzepatide, high oral dose of semaglutide, orforglipron, retatrutide, CagriSema, and survodutide. Given their structural and mechanistic diversity as well as their substantial efficacy and safety profiles, these medications and regimens are paradigm shifting and promise a brighter future. They will likely enable better disease prevention and management. This review will provide details about each of the above strategies to keep the scientific community up to date about progress in the fields of diabetes and obesity
科研通智能强力驱动
Strongly Powered by AbleSci AI